Drugmakers AbbVie and Amgen reached a patent-dispute settlement requiring Amgen to wait until 2023 to start selling a lower-priced copy of the world’s top-selling drug, AbbVie’s arthritis treatment Humira, in the U.S.
from WSJ.com: US Business http://ift.tt/2x0q02E
via IFTTT
No comments:
Post a Comment